Morocco has approved the emergency use of the AstraZeneca COVID-19 vaccine, jointly developed with the U.K.'s Oxford University.
The country's Health Ministry said Wednesday that the Serum Institute of India in under contract from AstraZeneca to make the shots.
Last month, the Moroccan government announced it had ordered 65 million doses of COVID-19 vaccines from China's Sinopharm and Britain's AstraZeneca. The country of 35 million people has not yet received the vaccines.
Approval of Sinopharm's vaccine is under review by Morocco's regulators and is expected to be granted in the coming days.
According to the authorisation documents, the AstraZeneca vaccine would be administered in two doses with an interval of between four and 12 weeks.
The approval comes as preparations for Morocco's vaccine rollout have reached advanced stages, the Health Ministry said. A launch date has not been announced.
The immunization plan aims to vaccinate 80 per cent of the population, including frontline workers and people suffering from chronic diseases. In response to rising coronavirus infections, Morocco imposed a nationwide curfew and ordered restaurants in major cities to close.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.